# Nyxoah cuts revenue outlook as U.S. adoption builds gradually

_Published Sunday, November 8, 2026 at 4:18 PM EST · Products · Latest · Tier 2 — Notable_

![The Globe and Mail — Primary](https://www.theglobeandmail.com/pf/resources/assets/meta/twitter-summary-240x240.png?d=988)

Nyxoah lowered its full-year 2026 revenue guidance to EUR 33 million-EUR 35 million, saying adoption of its Genio nerve stimulation therapy in the United States was progressing more gradually as physicians and treatment centers gained experience. Third-quarter global revenue reached EUR 9.2 million, up 365% from a year earlier.

The company trained 80 new surgeons and activated 53 accounts during the quarter. It also submitted an FDA application supplement seeking to expand Genio's indication to patients with complete concentric collapse. Cash equivalents and financial assets fell to EUR 77.1 million from EUR 97.8 million at June 30.

## Sources

- [The Globe and Mail](https://www.theglobeandmail.com/investing/markets/stocks/NYXH/pressreleases/8721779/nyxoah-earnings-call-highlights-growth-and-guidance-reset/)

---
Canonical: https://techandbusiness.org/newswire/dgq8bsd5mMU_4yjFaIZH2K
Published: 2026-11-08T21:18:22.256Z
Story chronology: 2026-11-08T20:58:00.000Z
Retrieved: 2026-11-09T00:12:31.403Z
Publisher: Tech & Business (techandbusiness.org)